Key Highlights
- Lilly opens its proprietary AI models to biotech startups while ensuring data privacy through federated computing
- Early participants include Insitro, Circle Pharma, Firefly Bio, and Superluminal Medicines — marking a new wave of AI-driven collaborations
- Part of Lilly’s Catalyze360 initiative, TuneLab strengthens the company’s role as a key innovation partner in early-stage life sciences
A bold move: Lilly democratizes AI for biotech
Eli Lilly has launched TuneLab, a novel AI platform designed to give biotech startups access to years of proprietary R&D data and advanced AI models. By opening its vault of “hundreds of thousands of unique molecules,” Lilly aims to accelerate discovery for smaller innovators while enhancing its own AI learning ecosystem. The distributed system ensures proprietary data from startups remains secure, positioning Lilly as a trusted enabler in drug development’s AI revolution.
Startups on board: from AI-powered drug design to oncology
Already, a dozen startups have joined TuneLab. Notable participants include Insitro, expanding its machine learning models with Lilly; Circle Pharma, focused on oncology drug candidates; Firefly Bio, advancing degrader-antibody conjugates; and Superluminal Medicines, working on GPCR-targeting AI therapeutics. Each brings a unique pipeline, showcasing the platform’s versatility across therapeutic areas.
AI infrastructure: built on federated computing
To balance collaboration with security, Lilly partnered with Rhino Federated Computing, which leverages Nvidia technology. Through a federated system, Lilly distributes AI models to local nodes at participating companies. Startups train these models with their own data, while anonymized updates improve the central AI engine. This model safeguards intellectual property while fueling collective innovation.
Strategic vision: Catalyze360 and beyond
TuneLab is a cornerstone of Lilly’s Catalyze360 initiative, which encompasses venture investments, lab space at Gateway Labs, and direct biotech partnerships. The move complements Lilly’s broader push into AI-enabled life sciences, alongside collaborations with Andreessen Horowitz on biotech investment funds. Lilly’s commitment reflects a shift from traditional M&A-heavy approaches to agile, collaborative ecosystems that nurture early innovation.
About Eli Lilly
Eli Lilly and Company is a global healthcare leader dedicated to creating medicines that make life better for people around the world. With a strong legacy in pharmaceutical innovation, Lilly combines cutting-edge science with partnerships that drive progress in biopharma, digital health, and AI-enabled drug discovery.
By